by Brooke Blazr | Dec 21, 2025 | High Dispatch
One of the most immediate ways we’ll experience the benefits of rescheduling cannabis is on medical and scientific research. Keeping cannabis in the Schedule I category imposed massive regulatory barriers that made it difficult to study the plant, even for renowned...
by Brooke Blazr | Dec 19, 2025 | High Dispatch
MJBizCon 2025 returned to Las Vegas with a familiar sense of scale—and a noticeably different tone. Drawing more than 20,000 cannabis industry professionals from across the globe, the industry’s largest annual business conference once again underscored why it remains...
by Brooke Blazr | Dec 19, 2025 | High Dispatch
When recurring sinus infections back in 2016 forced TribeTokes co-founder Degelis Pilla to cut back on smoking and vaping cannabis, she began searching for an alternative consumption method that would work just as well as inhalation for long-term use. She explored...
by Brooke Blazr | Dec 19, 2025 | High Dispatch
Trump’s executive order reclassifying weed as a Schedule III substance is breakthrough news for patients, researchers, and the cannabis industry as a whole. It doesn’t legalize weed nor does it legalize recreational use, but by removing federal barriers to research,...
by Brooke Blazr | Dec 18, 2025 | High Dispatch
Just when you thought the cannabis legalization train was unstoppable, reality is about to slap you in the face. According to a recent Vice article, several states are considering repealing their legal cannabis markets in 2026. That’s right—not just pausing...
by Brooke Blazr | Dec 16, 2025 | High Dispatch
The New Zealand Medicinal Cannabis Council (NZMCC) hosted its Industry Day on Oct. 29, 2025 at the EMA in Auckland, bringing together patients, clinicians, researchers, cultivators, advocates and policymakers for a full-day program centered on connection. The agenda...
